Home Page
KOFU, JAPAN--December 21, 2023--Researched by Industrial Info Resources (Sugar Land, Texas)--SK Bioscience (Seoul, South Korea) in June announced that its Phase 2 clinical trial of the 21 valence pneumococcal vaccine SKYPAC, which is being developed in collaboration with Sanofi (NASDAQ:SNY) (Paris, France), had successfully ended.
(All Fields Required)
Site-wide Scheduled Maintenance for September 27, 2025 from 12 P.M. to 6 P.M. CDT. Expect intermittent web site availability during this time period.
×Contact Us
For More Info!
